E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves

Gilde Healthcare and Norwest co-led round to commercialize the Hēlo® Thrombectomy Platform

MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2"), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE), today announced an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, as well as the two existing undisclosed strategic investors and a new global strategic investor.

The new financing supports commercialization of E2's novel Hēlo® Thrombectomy Platform for the treatment of pulmonary embolism, the third leading cause of cardiovascular death.